Big Pharma

AbbVie to Invest $1.4B in North Carolina Manufacturing Plant

Yuvraj — Fri, 24 Apr 2026 07:25:13 +0000

AbbVie has outlined plans to build a major new manufacturing facility in Durham, committing $1.4 billion to what will become its largest single-campus capital investment to date. The project, spread across 185 acres, is expected to generate more than 730 jobs and will support the production of medicines across the company’s immunology, neuroscience and oncology […]

The post AbbVie to Invest $1.4B in North Carolina Manufacturing Plant first appeared on World Pharma Today.

The Evolution of Field Execution in Specialty Pharma: From Coverage to Engagement

Yuvraj — Mon, 06 Apr 2026 08:17:20 +0000

Why Field Execution Must Evolve Field execution — how pharma companies organize, direct, and deliver commercial and medical interactions with healthcare professionals (HCPs), prescribers, and institutional decision-makers (collectively, “customers”) — is a major contributor to commercial success. Accordingly, over the past decade, companies have invested heavily in sales force effectiveness, key account management, omnichannel strategies, […]

The post The Evolution of Field Execution in Specialty Pharma: From Coverage to Engagement first appeared on World Pharma Today.

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal

Yuvraj — Fri, 03 Apr 2026 08:47:22 +0000

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic areas beyond its current core focus, particularly within neuroscience. Under the terms announced Tuesday, Lilly will […]

The post Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal first appeared on World Pharma Today.

Johnson & Johnson Wins DARZALEX Self-Administration EU Nod

Yuvraj — Wed, 01 Apr 2026 06:25:12 +0000

Johnson & Johnson has received a key regulatory endorsement in Europe, marking a significant shift in how oncology treatments can be administered. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has approved a Type II variation to the label of DARZALEX (daratumumab) subcutaneous (SC) formulation. This update allows patients […]

The post Johnson & Johnson Wins DARZALEX Self-Administration EU Nod first appeared on World Pharma Today.

Novartis China Investment Expands R&D and Manufacturing

Yuvraj — Tue, 24 Mar 2026 13:38:24 +0000

Novartis is stepping up its presence in China with a fresh wave of capital deployment, underscoring the country’s growing role in global pharmaceutical strategy. The company confirmed a Novartis China investment exceeding 3.3 billion Chinese yuan (roughly $480 million), aimed at expanding manufacturing capabilities in Beijing while advancing research operations in Shanghai. The announcement was […]

The post Novartis China Investment Expands R&D and Manufacturing first appeared on World Pharma Today.

Roche AI Factory Expansion to Boost Pharma R&D Capacity

Yuvraj — Wed, 18 Mar 2026 08:10:47 +0000

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure by deploying more than 2,100 NVIDIA chips, strengthening its computational capabilities to accelerate drug and diagnostics development. The move, centred on a large-scale Roche AI factory, reflects the company’s ongoing investment in advanced computing to streamline research and development processes across its global operations. The expansion […]

The post Roche AI Factory Expansion to Boost Pharma R&D Capacity first appeared on World Pharma Today.

Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal

Yuvraj — Thu, 26 Feb 2026 13:49:09 +0000

Novo Nordisk and Vivtex have formalised a collaboration aimed at advancing next-generation oral biologic therapies targeting obesity, diabetes and related comorbidities. Under the terms of the agreement, Vivtex will grant Novo Nordisk licences to selected oral drug-delivery technologies. In return, Vivtex will receive research funding, upfront payments and milestone payments that could total up to […]

The post Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal first appeared on World Pharma Today.

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Yuvraj — Thu, 19 Feb 2026 09:29:18 +0000

Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients living with both psoriasis and obesity in a late-stage study. The psoriasis trial enrolled 274 patients and evaluated whether the addition of Zepbound could enhance both dermatologic and weight-loss outcomes. After […]

The post Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data first appeared on World Pharma Today.

J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant

Yuvraj — Thu, 19 Feb 2026 08:41:29 +0000

Johnson & Johnson announced that it plans to invest more than $1 billion to construct a new cell therapy facility in Pennsylvania. The move forms part of the company’s broader strategy, unveiled last year, to expand its U.S. manufacturing base as President Donald Trump’s tariff threats continue to shape industry decisions. The Pennsylvania cell therapy […]

The post J&J to Invest $1 Billion in Pennsylvania Cell Therapy Plant first appeared on World Pharma Today.

AstraZeneca Breztri Reports Positive Phase III Trial Results

Yuvraj — Tue, 17 Feb 2026 09:31:31 +0000

Results from the Phase III KALOS and LOGOS trials evaluating AstraZeneca Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) in patients with uncontrolled asthma have been published in The Lancet Respiratory Medicine, reporting statistically significant and clinically meaningful improvements compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapies. The studies compared Breztri with Symbicort (budesonide/formoterol fumarate or […]

The post AstraZeneca Breztri Reports Positive Phase III Trial Results first appeared on World Pharma Today.